CD46 and neoplasm: Subcutaneously injected B16-CD46 cells formed tumors; however, CD46 expression was severely reduced in resected tumors at day 17, which may be due to increased immunogenicity of the CD46+ clones, as human CD46 may serve as a tumor antigen in this model.